Holen Sie sich die Stockscreener-App
4.00
1.01%
0.04
Schlusskurs vom Vortag:
$3.96
Offen:
$4.01
24-Stunden-Volumen:
747.11K
Relative Volume:
0.87
Marktkapitalisierung:
$215.75M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-2.5316
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-1.48%
1M Leistung:
-8.05%
6M Leistung:
-50.00%
1J Leistung:
-42.20%
1-Tages-Spanne:
$3.95
$4.075
1-Wochen-Bereich:
$3.90
$4.22
52-Wochen-Spanne:
$2.86
$13.70
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
4.00 | 215.75M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Acquires 97,565 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics Advances Pociredir for Sickle Cell Disease - TipRanks
Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - Defense World
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - MarketBeat
Suvretta Capital Management, LLC Acquires Additional Shares in F - GuruFocus.com
Geode Capital Management LLC Raises Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Barclays PLC Boosts Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Stifel Financial Corp Decreases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat
State Street Corp Increases Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
State Street Corp Boosts Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online
Fulcrum Therapeutics jumps amid takeover speculation - MSN
Fulcrum Therapeutics Receives Termination Notice from Sanofi Ending Collaboration Agreement for Losmapimod - Defense World
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump - Simply Wall St
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from S&P Pharmaceuticals Select Industry Index - Marketscreener.com
Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago - Yahoo Finance
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World
Charles Schwab Investment Management Inc. Acquires 393,202 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Charles Schwab Investment Management Inc. Has $2.03 Million Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics' SWOT analysis: stock faces headwinds after trial setback - Investing.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Holdings Trimmed by Fmr LLC - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Fmr LLC - Defense World
Fulcrum Therapeutics Insider Purchases Yet To Pay Off Regardless Of Recent Strength - Simply Wall St
Jacobs Levy Equity Management Inc. Takes $721,000 Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
BlackRock, Inc. Reduces Stake in Fulcrum Therapeutics Inc. - GuruFocus.com
Fulcrum Therapeutics' SWOT analysis: stock faces challenges after trial setback - Investing.com Nigeria
RA Capital Management L.P. Sells 1,380,605 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Braidwell LP Acquires New Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Makes New $474,000 Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why - MSN
Suvretta Capital Management LLC Sells 1,358,255 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics to Participate in Upcoming December Conferences - The Manila Times
Fulcrum Therapeutics to Present at Three Major Healthcare Conferences in December | FULC Stock News - StockTitan
CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz
Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche - The Globe and Mail
Fulcrum Therapeutics stock hits 52-week low at $2.87 By Investing.com - Investing.com Canada
Fulcrum Therapeutics stock hits 52-week low at $2.87 - Investing.com
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):